A therapeutic improvement: second generation tyrosine kinase inhibitors (TKI 2) in the treatment of chronic myelogenous leukemia

Marine Demarquet; Hélène Labussière-Wallet; Emmanuelle Nicolas-Virelizier; Franck-Emmanuel Nicolini

doi:10.1684/bdc.2011.1408



Printable version
A therapeutic improvement: second generation tyrosine kinase inhibitors (TKI 2) in the treatment of chronic myelogenous leukemia
Bulletin du Cancer. Volume 98, Number 8, 859-66, Août 2011, Synthèse
Résumé Texte intégral
Author(s) : Marine Demarquet, Hélène Labussière-Wallet, Emmanuelle Nicolas-Virelizier, Franck-Emmanuel Nicolini
Summary : Second-generation tyrosine kinase inhibitors (TKI 2) represent a recent important improvement in the treatment of Philadelphia positive leukemias. These agents are a suitable major option if resistance or significant imatinib intolerance occurs in chronic and accelerated phase CML. They are now introduced as first line therapy in chronic phase CML where they induce cytogenetic and molecular response rates never seen to date, which is promising for long-term survival. We propose here an analysis of the main current data available for the use of TKI 2 in CML.
Keywords : CML, imatinib, nilotinib, dasatinib, bosutinib, TKI 2